The future of CTCL therapy

3 Bekeken
administrator
administrator
08/09/23

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

  • categorie

Laat meer zien

0 Comments Sorteer op

Geen reacties gevonden

Facebook Reacties

Volgende